Validation and application of a death proxy in adult cancer patients

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 7, 2012, Pages 742-748

  Mealing, Nicole M ^a,b   Dobbins, Timothy A ^a   Pearson, Sallie Anne ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CENTRE FOR EPIDEMIOLOGY AND RESEARCH   (Australia)

Author keywords

Cancer; Observational studies; Outcomes assessment; Prescribing; Survival; Validation

Indexed keywords

TRASTUZUMAB;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CUSTODY; DEATH PROXY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; VALIDITY; VETERAN;

EID: 84863558209     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2257     Document Type: Article

References (18)

1. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA 2010; 304(8): 897-898.
2. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. The National Academies Press: Washington, DC, 2009.
3. Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer 2007; 96(4): 546-550.
4. Department of Health and Ageing. Medicare Benefits. [21 July 2011].
5. Department of Health and Ageing. 2011 PBS copayment and safety net amounts. [21 July 2011].
6. Department of Veterans' Affairs. Repatriation Pharmaceutical Benefits Scheme2010. DVA, Canberra; July 2010. [10 September 2010].
7. McManus P, Mant A, Mitchell P, et al. Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? Br J Clin Pharmacol 2001; 51(1): 93-98.
8. McManus P, Mant A, Mitchell P, et al. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry 2004; 38(6): 450-454.
9. Boyd IW, McEwen J, Calcino LJ. A study of codispensing with sodium alendronate in Australia. Br J Clin Pharmacol 2006; 61(4): 470-473.
10. Ringland C, Mant A, McGettigan P, et al. Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. Br J Clin Pharmacol 2008; 66(5): 682-688.
11. Pearson SA, Ringland C, Kelman C, et al. Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. Intern Med J 2007; 37(12): 798-805.
12. Roughead EE, Anderson B, Gilbert AL. Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 2007; 37(6): 402-405.
13. World Health Organization Collaborating Centre for Drug Statistics Methodology. Purpose of ATC/DDD System. Norwegian Institute of Public Health, Oslo; September 2009. [19 September 2010].
14. Esteban D, Whelan S, Laudico A, et al. Manual for Cancer Registry Personnel: IARC Technical Report No 10. International Agency for Research on Cancer: Lyon, 1995.
15. Barraclough H, Morrell S, Arcorace M, et al. Degree-of-spread artefact in the New South Wales Central Cancer Registry. Aust N Z J Public Health 2008; 32: 414-416.
16. Stavrou EP, McElroy HJ, Baker DF, et al. Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972-2005. Med J Aust 2009; 191: 310-314.
17. Percy C, Van Holten V, Muir C. ICD-O International Classification of Diseases for Oncology (3rd edn). WHO: Geneva, 1990.
18. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-Monitoring the effect of an expensive medicine access program. J Clin Oncol 2007; 25(24): 3688-3689.